262 related articles for article (PubMed ID: 32481505)
41. Interaction between NUDT15 and ABCC4 variants enhances intolerability of 6-mercaptopurine in Japanese patients with childhood acute lymphoblastic leukemia.
Tanaka Y; Nakadate H; Kondoh K; Nakamura K; Koh K; Manabe A
Pharmacogenomics J; 2018 Apr; 18(2):275-280. PubMed ID: 28418010
[TBL] [Abstract][Full Text] [Related]
42. Low NUDT15 expression levels due to biallelic NUDT15 variants and 6-mercaptopurine intolerance.
Yoshida M; Brown SA; Moriyama T; Nishii R; Tsujimoto SI; Yamada Y; Yoshida K; Shirai R; Osumi T; Utano T; Fukano R; Kudo K; Sakaguchi K; Arakawa Y; Koh K; Sekiguchi M; Sekimizu M; Miyamura T; Ishida H; Inukai T; Tomizawa D; Kiyokawa N; Kato M; Yang JJ
Br J Haematol; 2022 Oct; 199(2):270-276. PubMed ID: 35905175
[TBL] [Abstract][Full Text] [Related]
43. Histone deacetylase inhibitors induce FPGS mRNA expression and intracellular accumulation of long-chain methotrexate polyglutamates in childhood acute lymphoblastic leukemia: implications for combination therapy.
Leclerc GJ; Mou C; Leclerc GM; Mian AM; Barredo JC
Leukemia; 2010 Mar; 24(3):552-62. PubMed ID: 20072153
[TBL] [Abstract][Full Text] [Related]
44. TPMT and NUDT15 genes are both related to mercaptopurine intolerance in acute lymphoblastic leukaemia patients from Uruguay.
Soler AM; Olano N; Méndez Y; Lopes A; Silveira A; Dabezies A; Castillo L; da Luz JA
Br J Haematol; 2018 Apr; 181(2):252-255. PubMed ID: 28146264
[No Abstract] [Full Text] [Related]
45. The Effect of
Lee JM; Shim YJ; Kim DH; Jung N; Ha JS
Children (Basel); 2021 Mar; 8(3):. PubMed ID: 33804051
[TBL] [Abstract][Full Text] [Related]
46. APEX1 Polymorphism and Mercaptopurine-Related Early Onset Neutropenia in Pediatric Acute Lymphoblastic Leukemia.
Kim H; Seo H; Park Y; Min BJ; Seo ME; Park KD; Shin HY; Kim JH; Kang HJ
Cancer Res Treat; 2018 Jul; 50(3):823-834. PubMed ID: 28882023
[TBL] [Abstract][Full Text] [Related]
47. Interplay between IL6 and CRIM1 in thiopurine intolerance due to hematological toxicity in leukemic patients with wild-type NUDT15 and TPMT.
Kim H; You S; Park Y; Choi JY; Ma Y; Hong KT; Koh KN; Yun S; Lee KH; Shin HY; Lee S; Yoo KH; Im HJ; Kang HJ; Kim JH
Sci Rep; 2021 May; 11(1):9676. PubMed ID: 33958640
[TBL] [Abstract][Full Text] [Related]
48. Combination of common and novel rare
Zhu Y; Yin D; Su Y; Xia X; Moriyama T; Nishii R; Liao F; Zhang S; Guo X; Hou Q; Ai Y; Zhou X; Sun S; Zhang D; Zhang Y; Lin C; Deng Y; Lu X; Wang Y; Ma Z; Wang H; Liu B; Yang L; Zhang W; Yang JJ; Shu Y; Gao J; Xu H
Haematologica; 2018 Jul; 103(7):e293-e295. PubMed ID: 29519865
[No Abstract] [Full Text] [Related]
49. NUDT15 polymorphisms alter thiopurine metabolism and hematopoietic toxicity.
Moriyama T; Nishii R; Perez-Andreu V; Yang W; Klussmann FA; Zhao X; Lin TN; Hoshitsuki K; Nersting J; Kihira K; Hofmann U; Komada Y; Kato M; McCorkle R; Li L; Koh K; Najera CR; Kham SK; Isobe T; Chen Z; Chiew EK; Bhojwani D; Jeffries C; Lu Y; Schwab M; Inaba H; Pui CH; Relling MV; Manabe A; Hori H; Schmiegelow K; Yeoh AE; Evans WE; Yang JJ
Nat Genet; 2016 Apr; 48(4):367-73. PubMed ID: 26878724
[TBL] [Abstract][Full Text] [Related]
50. DNA-thioguanine nucleotide concentration and relapse-free survival during maintenance therapy of childhood acute lymphoblastic leukaemia (NOPHO ALL2008): a prospective substudy of a phase 3 trial.
Nielsen SN; Grell K; Nersting J; Abrahamsson J; Lund B; Kanerva J; Jónsson ÓG; Vaitkeviciene G; Pruunsild K; Hjalgrim LL; Schmiegelow K
Lancet Oncol; 2017 Apr; 18(4):515-524. PubMed ID: 28258828
[TBL] [Abstract][Full Text] [Related]
51. DNA-thioguanine nucleotide as a treatment marker in acute lymphoblastic leukemia patients with NUDT15 variant genotypes.
Ju HY; Lee JW; Cho HW; Hyun JK; Ma Y; Yi ES; Yoo KH; Sung KW; Choi R; Koo HH; Lee SY
PLoS One; 2021; 16(1):e0245667. PubMed ID: 33481917
[TBL] [Abstract][Full Text] [Related]
52. Prominence of NUDT15 genetic variation associated with 6-mercaptopurine tolerance in a genome-wide association study of Japanese children with acute lymphoblastic leukaemia.
Tanaka Y; Urayama KY; Mori M; Arakawa Y; Hasegawa D; Noguchi Y; Yanagimachi M; Keino D; Ota S; Akahane K; Inukai T; Hangai M; Kawaguchi T; Takagi M; Koh K; Matsuda F; Manabe A
Br J Haematol; 2022 Oct; 199(2):260-269. PubMed ID: 35961941
[TBL] [Abstract][Full Text] [Related]
53. Maintenance therapy and risk of osteonecrosis in children and young adults with acute lymphoblastic leukemia: a NOPHO ALL2008 sub-study.
Toksvang LN; Andrés-Jensen L; Rank CU; Niinimäki R; Nersting J; Nielsen SN; Mogensen SS; Harila-Saari A; Abrahamsson J; Joelsson J; Overgaard UM; Quist-Paulsen P; Griškevičius L; Jónsson ÓG; Vaitkevičienė G; Frandsen TL; Toft N; Grell K; Schmiegelow K
Cancer Chemother Pharmacol; 2021 Nov; 88(5):911-917. PubMed ID: 34145469
[TBL] [Abstract][Full Text] [Related]
54. Homozygote CRIM1 variant is associated with thiopurine-induced neutropenia in leukemic patients with both wildtype NUDT15 and TPMT.
Park Y; Kim H; Seo H; Choi JY; Ma Y; Yun S; Min BJ; Seo ME; Yoo KH; Kang HJ; Im HJ; Kim JH
J Transl Med; 2020 Jul; 18(1):265. PubMed ID: 32611418
[TBL] [Abstract][Full Text] [Related]
55. Methotrexate polyglutamate levels and co-distributions in childhood acute lymphoblastic leukemia maintenance therapy.
Nersting J; Nielsen SN; Grell K; Paerregaard M; Abrahamsson J; Lund B; Jonsson OG; Pruunsild K; Vaitkeviciene G; Kanerva J; Schmiegelow K;
Cancer Chemother Pharmacol; 2019 Jan; 83(1):53-60. PubMed ID: 30324220
[TBL] [Abstract][Full Text] [Related]
56.
Moradveisi B; Muwakkit S; Zamani F; Ghaderi E; Mohammadi E; Zgheib NK
Front Pharmacol; 2019; 10():916. PubMed ID: 31507415
[No Abstract] [Full Text] [Related]
57. Impact of NUDT15 genetics on severe thiopurine-related hematotoxicity in patients with European ancestry.
Schaeffeler E; Jaeger SU; Klumpp V; Yang JJ; Igel S; Hinze L; Stanulla M; Schwab M
Genet Med; 2019 Sep; 21(9):2145-2150. PubMed ID: 30728528
[TBL] [Abstract][Full Text] [Related]
58. NUDT15 variants confer high incidence of second malignancies in children with acute lymphoblastic leukemia.
Yoshida M; Nakabayashi K; Yang W; Sato-Otsubo A; Tsujimoto SI; Ogata-Kawata H; Kawai T; Ishiwata K; Sakamoto M; Okamura K; Yoshida K; Shirai R; Osumi T; Moriyama T; Nishii R; Takahashi H; Kiyotani C; Shioda Y; Terashima K; Ishimaru S; Yuza Y; Takagi M; Arakawa Y; Kinoshita A; Hino M; Imamura T; Hasegawa D; Nakazawa Y; Okuya M; Kakuda H; Takasugi N; Inoue A; Ohki K; Yoshioka T; Ito S; Tomizawa D; Koh K; Matsumoto K; Sanada M; Kiyokawa N; Ohara A; Ogawa S; Manabe A; Niwa A; Hata K; Yang JJ; Kato M
Blood Adv; 2021 Dec; 5(23):5420-5428. PubMed ID: 34662904
[TBL] [Abstract][Full Text] [Related]
59. Genetic polymorphisms in candidate genes predict increased toxicity with methotrexate therapy in Lebanese children with acute lymphoblastic leukemia.
Zgheib NK; Akra-Ismail M; Aridi C; Mahfouz R; Abboud MR; Solh H; Muwakkit SA
Pharmacogenet Genomics; 2014 Aug; 24(8):387-96. PubMed ID: 25007187
[TBL] [Abstract][Full Text] [Related]
60. Effect of polymorphisms in transporter genes on dosing, efficacy and toxicity of maintenance therapy in children with acute lymphoblastic leukemia.
Gervasini G; de Murillo SG; Jiménez M; de la Maya MD; Vagace JM
Gene; 2017 Sep; 628():72-77. PubMed ID: 28710036
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
